beebeeyan
2021-10-05
amc
Annovis Bio jumps 12% on positive ANVS401 data from Phase 2 Parkinson's disease study
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP,发表看法
APP内打开
发表看法
1
5
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":820772915,"tweetId":"820772915","gmtCreate":1633440109618,"gmtModify":1633440143483,"author":{"id":3581331692871918,"authorId":3581331692871918,"authorIdStr":"3581331692871918","name":"beebeeyan","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":34,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>amc</p></body></html>","htmlText":"<html><head></head><body><p>amc</p></body></html>","text":"amc","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/820772915","repostId":1171562230,"repostType":4,"repost":{"id":"1171562230","pubTimestamp":1633439209,"share":"https://www.laohu8.com/m/news/1171562230?lang=&edition=full","pubTime":"2021-10-05 21:06","market":"us","language":"en","title":"Annovis Bio jumps 12% on positive ANVS401 data from Phase 2 Parkinson's disease study","url":"https://stock-news.laohu8.com/highlight/detail?id=1171562230","media":"seekingalpha","summary":"Annovis Bio(NYSE:ANVS) gains 12% premarketafter announcing results from the completed dose response ","content":"<ul>\n <li>Annovis Bio(NYSE:ANVS) gains 12% premarketafter announcing results from the completed dose response Phase 2 clinical trial of ANVS401 in 54 Parkinson's disease (PD) patients, which found that once-daily ANVS401 was superior to placebo in improving motor function.</li>\n <li>The PD patients were treated with either 0mg, 5mg, 10mg, 20mg, 40mg or 80mg of ANVS401 once daily.</li>\n <li>ANVS401 has been found to be well-tolerated and safe with no adverse effects related to treatment observed.</li>\n <li>When compared to the placebo group, statistically significant improvements in Wechsler Adult Intelligence Scale (WAIS) coding scores were observed in PD patients taking ANVS401 5mg, 20mg and 80mg once daily, highlighting increased motor-dexterity, as well as speed and accuracy compared to placebo.</li>\n <li>PD patients treated with ANVS401 10mg and 20mg once daily showed statistically significant improvements in the MDS-Unified Parkinson's Disease Rating Scale compared to baseline.</li>\n <li>ANVS will request a meeting with the FDA to receive guidance on next steps in clinical development in light of the AD/PD Phase 2 clinical results.</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Annovis Bio jumps 12% on positive ANVS401 data from Phase 2 Parkinson's disease study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnnovis Bio jumps 12% on positive ANVS401 data from Phase 2 Parkinson's disease study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-05 21:06 GMT+8 <a href=https://seekingalpha.com/news/3748970-annovis-bio-jumps-12-on-positive-anvs401-data-from-phase-2-parkinsons-disease-study><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Annovis Bio(NYSE:ANVS) gains 12% premarketafter announcing results from the completed dose response Phase 2 clinical trial of ANVS401 in 54 Parkinson's disease (PD) patients, which found that once-...</p>\n\n<a href=\"https://seekingalpha.com/news/3748970-annovis-bio-jumps-12-on-positive-anvs401-data-from-phase-2-parkinsons-disease-study\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ANVS":"Annovis Bio, Inc."},"source_url":"https://seekingalpha.com/news/3748970-annovis-bio-jumps-12-on-positive-anvs401-data-from-phase-2-parkinsons-disease-study","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1171562230","content_text":"Annovis Bio(NYSE:ANVS) gains 12% premarketafter announcing results from the completed dose response Phase 2 clinical trial of ANVS401 in 54 Parkinson's disease (PD) patients, which found that once-daily ANVS401 was superior to placebo in improving motor function.\nThe PD patients were treated with either 0mg, 5mg, 10mg, 20mg, 40mg or 80mg of ANVS401 once daily.\nANVS401 has been found to be well-tolerated and safe with no adverse effects related to treatment observed.\nWhen compared to the placebo group, statistically significant improvements in Wechsler Adult Intelligence Scale (WAIS) coding scores were observed in PD patients taking ANVS401 5mg, 20mg and 80mg once daily, highlighting increased motor-dexterity, as well as speed and accuracy compared to placebo.\nPD patients treated with ANVS401 10mg and 20mg once daily showed statistically significant improvements in the MDS-Unified Parkinson's Disease Rating Scale compared to baseline.\nANVS will request a meeting with the FDA to receive guidance on next steps in clinical development in light of the AD/PD Phase 2 clinical results.","news_type":1},"isVote":1,"tweetType":1,"viewCount":101,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":3,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/820772915"}
精彩评论